Risk factors for familial and sporadic ovarian cancer among French Canadians: A case-control study

被引:55
作者
Godard, B
Foulkes, WD
Provencher, N
Brunet, JS
Tonin, PN
Mes-Masson, AM
Narod, SA
Ghadirian, P
机构
[1] Hop Hotel Dieu, Res Ctr, Epidemiol Res Unit, Montreal, PQ H2W 1T8, Canada
[2] McGill Univ, Montreal Gen Hosp, Dept Med, Div Med Genet, Montreal, PQ H3G 1A4, Canada
[3] Univ Montreal, Inst Canc Montreal, CHUM, Montreal, PQ H2L 4M1, Canada
[4] Womens Coll Hosp, Dept Med, Toronto, ON M5S 1B2, Canada
关键词
case-control; epidemiology; family history; ovarian cancer; risk factors;
D O I
10.1016/S0002-9378(98)70372-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The objective was to compare risk factors between familial and sporadic ovarian cancer by means of a case-control approach. STUDY DESIGN: We conducted a case-control study among French Canadian women in Montreal during 1995-1996. One hundred seventy women 20 to 84 years old with histologically confirmed diagnoses of primary ovarian carcinomas or borderline tumors were interviewed concerning their reproductive, family and medical histories. During the same period 170 randomly selected population control subjects, frequency-matched to the case patients according to age and ethnic group, were also interviewed. Unconditional logistic regression methods were used for data analysis. RESULTS: The major factors influencing the risk of development of ovarian cancer were as follows: (1) family history of breast or ovarian cancer, (2) a late age at use of oral contraceptives (a protective effect), and (3) a late age at last childbirth (a protective effect for familial case patients only). CONCLUSION: These factors had equally great impacts in familiar and sporadic cases, implying that the underlying mechanisms of carcinogenesis in sporadic and familiar ovarian cancer may be similar and that hereditary ovarian cancer may be preventable.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 48 条
[1]  
Adams CS, 1994, ADV ATOM MOL OPT <D>, V34, P1
[2]  
CASAGRANDE JT, 1979, LANCET, V2, P170
[3]  
CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711
[4]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[5]  
Easton DF, 1996, INT J CANCER, V65, P284, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt
[6]  
284::AID-IJC2&gt
[7]  
3.0.CO
[8]  
2-W
[9]  
Foulkes WD, 1995, CLIN INVEST MED, V18, P473
[10]  
Friedman E., 1996, American Journal of Human Genetics, V59, pA67